CMA Helps Diagnose Developmental Disorders in Children
This study looked at the use of chromosomal microarray analysis (CMA) in diagnosing children with developmental and congenital issues.
This hub covers epilepsy genetics: how gene changes can contribute to seizures (often in children). We translate studies on testing, results like VUS, and what findings may change for care.
No. It’s common in pediatrics, but adults can benefit from genetic testing, too, especially with unclear diagnosis or family history.
Sometimes. For certain conditions, results can guide medication choice, diet therapies, or referral decisions.
It usually means “not enough evidence yet.” It shouldn’t be treated as a definite cause, but it can be reclassified over time.
Not necessarily. Testing can miss some variants, and new gene links are still being discovered.
This study looked at the use of chromosomal microarray analysis (CMA) in diagnosing children with developmental and congenital issues.
This study looked at how involving parents in the care of children and teenagers with chronic illnesses, like epilepsy, can affect their quality of life and health outcomes.
This study looked at different types of corpus callosotomy (CC), a surgery used to help children with severe epilepsy that doesn’t respond to medication.
Researchers studied the use of nicotine as a treatment for Sleep-Related Hypermotor Epilepsy (SHE), a type of epilepsy that can have a genetic cause.
Researchers studied a 9-year-old girl with a rare movement disorder linked to a mutation in the GNAO1 gene.
This study looked at the effects of a plant extract called Ammi visnaga, commonly known as the toothpick plant, on seizures in mice.
Researchers studied the use of third-generation anti-seizure medications in people with epilepsy.
Researchers studied myoclonic epilepsy with ragged-red fibers (MERRF), a rare condition caused by changes in mitochondrial DNA.
This study looked at pediatric epilepsy in Palestine, focusing on children aged 2 months to 18 years who were diagnosed between 2019 and 2024.